Research article · 2014
Conference abstractPublished 26 Nov 2012
Tissue plasminogen activator: Beyond a protease
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
t PA, a member of the serine protease family, plays a pivotal role in the homeostasis of blood coagulation/fibrinolysis and matrix regulation, and is the FDA-approved first choice for ischemic stroke and acute myocardial infarction. However, its clinical usage has been significantly damped by its nonprotease-related side effects and toxicity. Our previous studies discovered that tPA is a hybrid molecule with dual functions: protease and cytokine. As a protease, tPA converts plasminogen into active plasmin and participates in the fibrinolysis and matrix degradation. As a cytokine, tPA activates numerous receptor-mediated cellular signal transduction events contributing to its undesirable side effects and toxicity. tPA as a cytokine, plays a detrimental role in the pathogenesis of kidney fibrosis through multiple molecular mechanisms: 1) induces matrix metalloproteinases production through MAPK pathway triggering the epithelial mesenchymal transition; 2) promotes the survival, proliferation, and interstitial accumulation of fibroblasts in the diseased kidneys through p90RSK signaling; 3) promotes myofibroblast activation and macrophage migration by activating integrin signals; 4) modulates inflammation via NF-Ã?ºB activation. It is clear that tPA mediates its renal toxicity and side effects through its cytokine functions. Thus, better understanding of the mechanisms of tPA actions will eventually lead to the development of novel therapeutic strategies targeting its cytokine functions while retaining its beneficial protease activities
Subjects
ToxicologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Perspective · 27 May 2024
Correlations between Tissue Plasminogen Activator Levels and Adiposity after Exercise-induced Weight Loss
Article · 17 Apr 2024
Harnessing the Power of Recombinant Tissue-Type Plasminogen Activator: A Breakthrough in Stroke Treatment
Perspective · 30 Jun 2021
First Known Use of Tissue Plasminogen Activator
Research article · 2020
A Case of Oropharyngeal Angioedema Following Intravenous Recombinant Tissue Plasminogen Activator (rt‐PA) and Mechanical Thrombectomy
More from this journal
The newest in Journal of Clinical Toxicology.
Commentary · 8 Apr 2026
Occupational Chlorfenapyr Poisoning: Clinical Implications and Research Value Under Hidden Risks
Perspective · 25 Feb 2026
Toxicological and Health Effects: Mechanisms, Exposure Routes and Prevention Strategies
Case report · 23 Feb 2026
Case Report: Methaemoglobinaemia Following Indoxacarb Ingestion
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Clinical Toxicology
- SubjectToxicology
- BylineArticles whose byline prints “Kebin Hu”

